MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
- Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
- In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
- Imugene, which has offices in the United States and Australia, is focused on developing transformative cancer medicines to improve patients’ lives.
- Imugene is MaxCyte’s 25th SPL overall, which generates pre-commercial milestone revenue, the vast majority of which includes post-commercial revenue.